Industry Supported Sessions

* Please see below the full programme​

​​​​​Saturday, October 24, 2015

​Time​Apollon​Athéna
​13:00 - 14:30​AstraZeneca
​17:00 - 18:30​​F. Hoffmann-La Roche Ltd


Sunday, October 25, 2015

​​​​​TimeAthéna
13:00 - 14:30​PharmaMar​
17:30 - 19:00​AstraZeneca​


​​​Saturday, October 24, 2015​

BRCAm OVARIAN CANCER: WHO AND HOW TO TREAT – EXPERT'S RECOMMENDATION IN CLINICAL PRACTICE

13:00 – 14:30, Athéna
Symposium Organised and Supported by AstraZeneca

Chair: Andreas du Bois (Germany)

13:00 – 13:10

THE TREATMENT OF PLATINUM-SENSITIVE RECURRENT BRCAm ​OVARIAN CANCER
Andreas du Bois (Germany)

13:10 – 13:40

DIAGNOSTICS - HOW TO SELECT AND WHAT IS NEEDED

  • BRCAm is sufficient
  • Using signatures and scars

Ursula Matulonis (USA)
Jonathan Ledermann (UK)

13:40 – 14:05

ONCE YOU HAVE MADE THE DIAGNOSIS - WHEN AND HOW TO TREAT? HOW TO MANAGE ADVERSE EVENTS, DEFINE PROGRESSION, AND STOP TREATMENT IN THE CLINICAL SETTING
Eric Pujade-Lauraine (France)

14:05 – 14:20

DISCUSSION – Q&A
All

14:20 – 14:30

S​UMMARY AND MEETING CLOSE
Andreas du Bois (Germany)


________________________________________________________________________

PATIENT OUTCOMES IN FOCUS: SELECTION AND SEQUENCING DECISIONS IN THE TREATMENT OF OVARIAN CANCER

17:00 – 18:30, Apol
lon
Symposium Organised and Supported byF. Hoffmann-La Roche Ltd​

​Chair: Nicoletta Colombo (Italy) 

 

WELCOME AND INTRODUCTION
Nicoletta Colombo (Italy)

17:00 – 17:20

INITIAL MANAGEMENT OF ADVANCED EPITHELIAL OVARIAN CANCER
Andreas du Bois (Germany) 

17:20 – 17:40

PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER
Eric Puj​ade-Lauraine (France) 

17:40 – 18:00

DOES THE FINDING OF A BRCA MUTATION ALTER THE TREATMENT ALGORITHM FOR PATIENTS WITH PLATINUMSENSITIVE RELAPSE OF OVARIAN CANCER?
Ignace Vergote (Belgium)

18:00 – 18:20

ASSESSING NOVEL OPTIONS FOR PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER
Eric Pujade-Lauraine (France) 

18:20 – 19:30

MAKING SENSE OF SEQUENCING OPTIONS FOR OVARIAN CANCER
Nicoletta Colombo (Italy) 

 

CONCLUDING REMARKS
Nicoletta Colombo (Italy)​​ 


Sunday, October 25, 2015

MAKING THE MOST OF EVERY OPTION IN THE TREATMENT OF OVARIAN CANCER. CHOOSING THE OPTIMAL SEQUENCE

13:00 – 14:30, Athéna
Symposium Organised and Supported by PharmaMar

y)​

– 13:10

CHAIR'S WELCOME AND INTRODUCTION
Andreas du Bois (Germany)

13:10 – 13:30

MANAGEMENT OF RECURRENT OVARIAN CANCER: FACTORS TO CONSIDER
Antonio González-Martín (Spain)

13:30 – 13:40

BENEFITS OF RECHALLENGING PATIENTS WITH PPS RELAPSES WITH A NON-PLATINUM COMBINATION

Anne-Claire Hardy-Bessard (France)

13:40 – 13:50

BRCA STATUS MATTERS… AND SO DOES PFI
Gabriella Ferrandina​ (Italy) 

13:50 – 14:00

HANDLING HYPERSENSITIVE REACTIONS TO PLATINUM. A DIFFERENT APPROACH
Ignacio Romero (Spain) 

14:00 – 14:10

GETTING USED TO DIFFERENT SAFETY PROFILES
Christian Marth (Austria) 

14:10 – 14:20

DISCUSSION
All 

14:20 – 14:30

CHAIR'S CONCLUSIONS
Nicoletta Colombo (Italy) 


________________________________________________________________________

THE FUTURE OF ANGIOGENESIS IN OVARIAN CANCER

17:30 – 19:00, Athéna
Symposium Organised and Supported by AstraZeneca

Chair: Jalid Sehouli (Germany)

17:30 – 1​​7:35

WELCOME

17:35 – 18:00

PLATINUM SENSITIVE RELAPSED PATIENTS, WHAT CAN WE DO POST FIRST LINE?
Shibani Nicum (UK)

18:00 – 18:25

ANGIOGENESIS AND MECHANISMS OF RESISTANT PATHWAYS
An Reyners (The Netherlands) 

18:25 – 18:50

HOW MIGHT COMBINATIONS ENHANCE CLINICAL OUTCOMES?
Joyce Liu (USA) 

18:50 – 19:00

PANEL DISCUSSION – Q&A
All 



Keep Me Updated